Type | Subsidiary |
---|---|
Industry | Cryolipolysis |
Founded | 2005 |
Founder | Mitchell Levinson |
Headquarters | , United States |
Key people | Mark J. Foley, president and chief executive officer |
Products | CoolSculpting Procedure |
Parent | Allergan plc |
Website | zeltiq![]() |
Zeltiq Aesthetics is a subsidiary of AbbVie based in Pleasanton, California that markets and licenses devices used for cryolipolysis procedures. The company was founded in 2005 and raised $75 million in funding before going public in 2011. It was acquired by Allergan in February 2017 for $2.48 billion. [1] [2] [3] Which was then acquired by AbbVie in 2020 for $63 billion. [4]
Zeltiq was founded in 2005 as Juniper Medical, Inc., by Mitch Levinson, who had previously led Thermage, a company that sold devices for radio frequency skin tightening. [5] [6] The company changed its name to Zeltiq in July 2007. [7]
The company developed a medical device to remove fat using a process called cryolipolysis, which it branded as "CoolSculpting". [8] The device works by pulling a piece of flesh between two paddles, which cool it to below freezing and hold the temperature there for a half hour or so. Afterwards the flesh is frozen and numb; the numbness persists for two to three months. [9] For the clinics that use it, there is a high capital investment, and a room is tied up for a relatively long time. [9] It is intended for body contouring and not general weight loss. As of 2013, clinical trials have found that Cryolipolysis is moderately effective and has mostly mild and temporary side effects. [10]
Cryolipolysis was invented by Rox Anderson and colleagues [11] and Juniper Medical exclusively licensed patent filings on the invention from Massachusetts General Hospital when Juniper was founded. [6] An early prototype was created to test the method on pigs, [12] and preliminary results from a clinical trial were reported in 2009. [11]
In 2009 Gordie Nye was appointed CEO, replacing Levinson, who remained on the board. [13] [14]
Zeltiq brought the device to market first for use in numbing the skin prior to dermatology procedures being done; Zeltiq received FDA clearance to market it for this purpose under the de novo pathway in 2010. [15] [16] While the company did not market its device for removing fat at that time, doctors on its scientific board were talking about that use at scientific meetings and on TV news, and doctors started using it off-label for "body-sculpting". [17] [18]
The company made money from selling the machines, and also charged doctors for each procedure they did with the machine. [5] Because the procedure was elective surgery, people paid out of pocket for it. [17] By the end of 2010, the company had raised $75 million in financing over four rounds of funding. [19]
The device received FDA clearance to be marketed for removing love handle fat from people's sides in September 2010 [20] and from the stomach in 2012. [20] It has also been approved by Health Canada and the European Union. [21] By late 2010 CoolSculpting had been introduced as a body-sculpting procedure in Europe, Asia and Canada. [22] By 2011, Zeltiq was approved to market the procedure in 46 countries. [23]
CoolSculpting became popular in the United States around 2011. [20] In the first half of that year, Zeltiq's revenues grew four-fold to $31.6 million, though it was still operating at a small loss. [5] [23] Zeltiq filed for an initial public offering later that year. [5] [23] The IPO raised $91 million. [24]
By January 2012, there had been 150,000 CoolSculpting treatments. [25] In 2014, Zeltiq introduced a new model of the CoolSculpting device obviating the suction cup and was cleared by the FDA for use on thighs. [26] [27]
As of 2014 the company's device led the market for cryolipolysis. [28] [9] [29] [30]
In February 2017 Zeltiq was purchased by Allergan for $2.48 billion. [2] [3]
As of June 2020, CoolSculpting has been cleared to treat the abdomen, love handles (flanks) upper arm, back fat, bra fat, banana roll, submental area, and thighs. [31]
Linda Evangelista claims CoolSculpting procedure she underwent resulted in an uncommon side effect paradoxical adipose hyperplasia, experienced by under 1% of the patients, and causing fatty tissue to thicken and expand, the outcome contrary to the expected from the procedure. [32] Other studies, however, indicate that side effects are common on a per-patient basis, since a typical patient receives multiple treatments. [33]
Side effects under 1% (1 on 100) are called: "uncommon" by EMA, while they need to be under 1 on 1,000, to be called: "rare" and under 1 on 10,000, to be called: "very rare". If the side effect equals 1%, EMA scale calls it a "common" side effect. [34]
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Mesotherapy is a form of alternative medicine which involves intradermal or subcutaneous injections of pharmaceutical preparations, enzymes, hormones, plant extracts, vitamins, and/or other ingredients such as hyaluronic acid. It has no proven clinical efficacy and poor scientific backing. Mesotherapy injections allegedly target adipose fat cells, apparently by inducing lipolysis, rupture and cell death among adipocytes. The stated aim of mesotherapy is to provide the skin with essential nutrients, hydration, and other beneficial compounds to rejuvenate and revitalize its appearance.
Laser hair removal is the process of hair removal by means of exposure to pulses of laser light that destroy the hair follicle. It had been performed experimentally for about twenty years before becoming commercially available in 1995 and 1996. One of the first published articles describing laser hair removal was authored by the group at Massachusetts General Hospital in 1998. Laser hair removal is widely practiced in clinics, and even in homes using devices designed and priced for consumer self-treatment. Many reviews of laser hair removal methods, safety, and efficacy have been published in the dermatology literature.
Breast augmentation and augmentation mammoplasty is a cosmetic surgery technique using breast-implants and fat-graft mammoplasty techniques to increase the size, change the shape, and alter the texture of the breasts. Augmentation mammoplasty is applied to correct congenital defects of the breasts and the chest wall. As an elective cosmetic surgery, primary augmentation changes the aesthetics – of size, shape, and texture – of healthy breasts.
Medtronic plc is an American medical device company. The company's operational and executive headquarters are in Minneapolis, Minnesota, and its legal headquarters are in Ireland due to its acquisition of Irish-based Covidien in 2015. While it primarily operates in the United States, it operates in more than 150 countries and employs over 90,000 people. It develops and manufactures healthcare technologies and therapies.
Reconstructive surgery is surgery performed to restore normal appearance and function to body parts malformed by a disease or medical condition.
Gluteoplasty denotes the plastic surgery and the liposuction procedures for the correction of the congenital, traumatic, and acquired defects and deformities of the buttocks and the anatomy of the gluteal region; and for the aesthetic enhancement of the contour of the buttocks.
Allergan, Inc. was an American global pharmaceutical company focused on eye care, neurosciences, medical dermatology, medical aesthetics, breast enhancement, obesity intervention and urologics. Allergan, Inc. was formed in 1948, incorporated in 1950 and became a public company in 1970. It ceased operation in 2015 when it was acquired by Irish-based Actavis plc, who then renamed the group as Allergan plc.
Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.
Richard Rox Anderson, FAAD, is a Boston-based dermatologist and entrepreneur.
A breast implant is a prosthesis used to change the size, shape, and contour of a person's breast. In reconstructive plastic surgery, breast implants can be placed to restore a natural looking breast following a mastectomy, to correct congenital defects and deformities of the chest wall or, cosmetically, to enlarge the appearance of the breast through breast augmentation surgery.
Liposuction, or simply lipo, is a type of fat-removal procedure used in plastic surgery. Evidence does not support an effect on weight beyond a couple of months and does not appear to affect obesity-related problems. In the United States, liposuction is the most common cosmetic surgery.
Aesthetic medicine is a branch of modern medicine that focuses on altering cosmetic appearance through the treatment of conditions including scars, skin laxity, wrinkles, moles, liver spots, excess fat, cellulite, unwanted hair, skin discoloration, and spider veins. Traditionally, it includes dermatology, oral and maxillofacial surgery, reconstructive surgery and plastic surgery, surgical procedures, non-surgical procedures, and a combination of both. Aesthetic medicine procedures are usually elective. There is a long history of aesthetic medicine procedures, dating back to many notable cases in the 19th century, though techniques have developed much since then.
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
Acelity L.P. Inc., was a privately held medical device company. It was a non-operating holding company whose wholly owned subsidiaries developed advanced wound therapeutics products. The advanced wound therapeutics business was conducted by Kinetic Concepts, Inc. (KCI) and its subsidiaries, including Systagenix.
Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.
Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
Fat removal procedures are used mostly in cosmetic surgery with the intention of removing unwanted adipose tissue. The procedure may be invasive, as with liposuction, or noninvasive using laser therapy, radiofrequency, ultrasound or cold to reduce fat, sometimes in combination with injections.
Brent Saunders is an American biopharma executive, entrepreneur, and chief executive officer and chairman of eye health company Bausch & Lomb. He is helped lead various mergers and acquisitions and overseen the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He is the founder of special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthetics companies The Beauty Health Company and Hugel America.